HALEON PLC at Exane BNP Paribas European CEO Conference Transcript
Over to you, Brian.
Yes. Thanks so much, Jeff, for that introduction. I appreciate that. So listen, I'll leave it to all of you at your own time to read the customary disclaimer. So it's great to be here today to talk to you about GSK Consumer Healthcare, the world leader in consumer healthcare, competing in GBP130 billion market that's been growing at about 3.5% a year.
And to talk to you about our exciting journey to separation and listing, which is scheduled to happen in mid-2022. We have a great opportunity ahead of us. At the time of listing, we'll be the first and only listed company 100% focused on consumer health. And with that, we bring a unique combination of a scientific heritage and capability that comes from being part of a pharma company with strong FMCG skills that we've built over time.
Now, this really comes to life in our oral health business, where you see Sensodyne, which is our largest brand, has been able to grow double digits over the
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |